Plamotamab (XmAb^®13676) for Ibrutinib- refractory CXCR4-mutated extramedullary Waldenström macroglobulinemia

Click to increase image sizeClick to decrease image size

Disclosure statement

R.D.P., V.A., V.R., D.M.M., L.J. and A.A.C.K have no conflicts of interest to declare.

S.A receives honoraria from Celgene and Takeda as well as research funding from Amgen, Janssen, Pharmacyclics, Cellectar, Bristol Myers Squibb, Medimmune and Phosplatin.

D.L., C.J. and R.C. are employed by Xencor, Inc. and have equity in the company.

The remaining authors declare no competing financial interests.

Author contributions

Contribution: R.D.P., D.M.M., L.J., and S.A. designed the research, performed the research, analyzed data, and wrote the manuscript; A.A.C.K, V.R., V.A., performed the research, designed the research and analyzed data; D.L, and C.J. designed and are conducting the clinical study on behalf of Xencor. R.C. developed the and implemented the biomarker plan for the study; and all authors provided feedback and approved the manuscript.

Data availability statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Additional information

Funding

This work was supported by Error! Hyperlink reference not valid..